Raymond Woo Sells 11,112 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 11,112 shares of CeriBell stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $21.18, for a total transaction of $235,352.16. Following the sale, the chief technology officer owned 167,317 shares of the company’s stock, valued at $3,543,774.06. The trade was a 6.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Raymond Woo also recently made the following trade(s):

• On Monday, December 1st, Raymond Woo sold 11,112 shares of CeriBell stock. The stock was sold at an average price of $12.28, for a total value of $136,455.36.
• On Tuesday, November 11th, Raymond Woo sold 11,112 shares of CeriBell stock. The shares were sold at an average price of $12.28, for a total value of $136,455.36.

CeriBell Trading Up 5.1%

Shares of NASDAQ:CBLL opened at $22.83 on Thursday. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12. CeriBell, Inc. has a 52-week low of $10.01 and a 52-week high of $26.04. The stock has a market cap of $846.99 million, a price-to-earnings ratio of -15.12 and a beta of 1.02. The business has a 50-day moving average price of $17.54 and a 200-day moving average price of $15.03.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.06. The company had revenue of $22.59 million for the quarter, compared to the consensus estimate of $21.78 million. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. Equities analysts predict that CeriBell, Inc. will post -2.46 EPS for the current year.

Hedge Funds Weigh In On CeriBell

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CBLL. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of CeriBell during the 3rd quarter worth about $33,000. Tower Research Capital LLC TRC boosted its stake in shares of CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after acquiring an additional 1,801 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in shares of CeriBell by 97.5% during the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after purchasing an additional 1,256 shares in the last quarter. Police & Firemen s Retirement System of New Jersey raised its stake in CeriBell by 161.0% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock valued at $106,000 after purchasing an additional 3,502 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC purchased a new position in CeriBell in the 3rd quarter valued at $135,000.

Analyst Ratings Changes

Several equities analysts have recently issued reports on CBLL shares. Raymond James Financial assumed coverage on CeriBell in a report on Tuesday, October 21st. They issued a “strong-buy” rating and a $19.00 price objective for the company. TD Cowen decreased their price target on CeriBell from $36.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Canaccord Genuity Group upped their price objective on CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. BTIG Research reaffirmed a “buy” rating and set a $30.00 target price on shares of CeriBell in a report on Monday, December 15th. Finally, Cowen restated a “buy” rating on shares of CeriBell in a research report on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, CeriBell has an average rating of “Moderate Buy” and a consensus target price of $24.67.

CeriBell News Summary

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: FDA Breakthrough Device designation for CeriBell’s AI-based LVO stroke detection and monitoring system — this raises the product’s regulatory profile, can accelerate review and hospital access, and improves the commercial/clinical outlook. Ceribell Receives FDA Breakthrough Device Designation
• Neutral Sentiment: Widespread media/analyst coverage of the Breakthrough designation is amplifying investor attention and likely driving short‑term buying interest. Zacks: CBLL Wins FDA Breakthrough Status
• Neutral Sentiment: Recent fundamentals: the company beat last quarter’s revenue and EPS estimates but remains unprofitable with negative margins and consensus forecasts for full‑year negative EPS — supports growth narrative but highlights execution/profitability risk.
• Negative Sentiment: CEO Xingjuan Chao sold 79,000 shares at ~$21.27 on Jan. 2 (≈9.6% reduction of her holding). Insider selling at this scale can be viewed negatively by some investors. SEC Filing: Xingjuan Chao
• Negative Sentiment: CTO Raymond Woo sold 11,112 shares at ~$21.18 on Jan. 2 (≈6.2% reduction). SEC Filing: Raymond Woo
• Negative Sentiment: VP David Foehr sold 5,556 shares at ~$22.60 and Director Rebecca Robertson sold 2,500 shares at ~$21.89 — several small-to-mid insider reductions in the same window can temper enthusiasm. SEC Filing: David Foehr SEC Filing: Rebecca B. Robertson

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.